WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.453
Volume 14, Issue 5, 240-263. Review Article ISSN 2277–7105

METABOLIC DYSFUNCTION: A COMPREHENSIVE REVIEW OF PATHOPHYSIOLOGY AND TREATMENT STRATEGIES

Rushikesh S. Wandhekar[1]*, Santosh B. Dighe[2], Achal K. Labade[1] and Kalyani A. Kavade[1]

[1]Department of Pharmacology, Pravara Rural College of Pharmacy, Pravaranagar, MH, India 413736.

[2]Associate Professor, Department of Pharmacology, Pravara Rural College of Pharmacy, Pravaranagar, MH, India 413736.

Article Received on 04 January 2025,
Revised on 24 Jan. 2025,
Accepted on 14 Feb. 2025
DOI: 10.20959/wjpr20255-35682

***Corresponding Author**
Rushikesh S. Wandhekar
Department of Pharmacology, Pravara Rural College of Pharmacy, Pravaranagar, MH, India 413736.

ABSTRACT

Metabolic dysfunction is a class of diseases that impair normal biochemical function, resulting in significant health impacts. Etiology of such malfunction arises through complex interactions among genetic, environmental, and lifestyle factors. The key mechanisms in pathophysiology involved are insulin resistance, chronic inflammation, and oxidative stress leading to complications like cardiovascular disease and renal impairment. This shall require a holistic approach in the management, including lifestyle changes, pharmacological treatments, and public health measures for prevention. In order to empower the population towards a healthy diet and regular exercise, education of the population on healthy diets and regular exercises will be required. The knowledge of genetic susceptibility and the exploration of potential therapeutic agents should further be researched to devise more potent interventions. Public health interventions will be improving access to healthy food and increasing physical activity in communities and regular screening for the risk factors of metabolic syndrome. Support groups will provide emotional support to the individual dealing with such conditions. Co-operation between healthcare providers, researchers, and community organizations can create an environment that places a priority on metabolic health. Indeed, metabolic dysfunctions are approached with integrative strategies which lead to good health outcomes by individuals as well as reduce the marvelous economic load on healthcare systems in the world. Metabolic disorders' understanding is very

vital toward developing meaningful preventive strategies as well as helping therapeutic intervention to public health.

KEYWORDS: Metabolic dysfunction, Insulin Resistance, Chronic Inflammation, Adipose Tissue, Pharmacological Interventions, Lifestyle Modifications.

INTRODUCTION

Metabolic disorders correspond to the spectrum of diseases influencing normal biochemical processes within an organism, thereby altering the manner of conversion of nutrients into energy and balance of various substances.[1] Many conditions fall into this range, such as diabetes, obesity and metabolic syndrome.[1,2] The causes can be genetic mutations; organ dysfunctions, particularly in functions of endocrine glands; or external influences affecting metabolic pathways.[1,3] Metabolic dysfunction fundamentally indicates a disturbance in ability to metabolize macronutrients, including proteins, fats, carbohydrates, resulting in considerable health implications.[4]

Metabolism is the complex network of biochemical processes occurring in living organisms to sustain life.[1] The whole system can be broadly divided into two processes: catabolism and anabolism.[5] Catabolic reactions are essentially the degradation of larger molecules into smaller units with the release of energy.[5] A relevant example would be the breakdown of carbohydrates into glucose, which acts as a storage reservoir of energy for cellular activities.[6] In contrast, anabolism is the process of building large molecules from small components and requires energy to fuel crucial functions such as the growth of cells and tissue repair.[1,3] It does not end with cellular activity for metabolism serves as the foundation of holistic health and homeostatic regulation.[7] Metabolic processes affect physiological parameters including body temperature, pH level, and concentrations of many materials within cellular environments.[1,7] What's more, metabolism is fundamental to the direction of trends in population health, meaning growing incidence of metabolic disorder like obesity and diabetes affects gigantic impacts on health care across the world.[7,8] Understanding metabolism is important for individual health as well as to address the larger health concerns in communities.[6]

Metabolic dysfunction is caused by some form of disruption in the complexity of metabolic processes.[8] Such a disruption can lead to a multitude of health issues with far-reaching consequences.[8] One of the most commonly known examples is diabetes mellitus, which involves impaired insulin function.[8,9] In Type 1 diabetes, autoimmune reaction kills insulin producing cells.[7,10] Type 2 diabetes is commonly associated with the lifestyle factors that cause it, such as poor diet and lack of exercise.[9]

The metabolic syndrome is common expression of metabolic dysfunction is.[1,3] This is group of conditions, including hypertension, high blood glucose, excess fat accumulation around the abdominal region, and abnormal cholesterol levels.[7] Metabolic syndrome poses an enormously increased threat of cardiovascular diseases and strokes.[2] It is very much associated with obesity and a sedentary lifestyle.[11] Inherited metabolic disorders result from genetic mutations leading to enzyme deficiencies or abnormalities.[3,11] Examples include phenylketonuria (PKU) and Gaucher's disease; earlier diagnosis via newborn screening may result in better outcomes through dietary management or other interventions.[12,13]

The effects of metabolic disturbances are numerous and intricate.[1,3] Most chronic diseases that arise due to these disorders can strongly affect an individual's level of life and life span.[12,14] For example, a severe complication of diabetes can present with various diseases, such as heart conditions, renal impairment, neuropathy, or even amputations in very severe cases.[15,16] Additionally, financial pressure resulting from treatment of chronic conditions caused by metabolic disorder presents enormous challenges for all healthcare systems across the world.[4,14] The importance of metabolic dysfunction, in addition to its significance in health, lies in its need for increasing public health awareness; in the wake of the increased prevalence of obesity and related conditions all over the world, a much more effective public health intervention in prevention and management is indeed the need of the hour.[4,5,15] Understanding the risks associated with metabolic dysfunction can help the better steps taken toward healthy living.[3]

From a clinical perspective, it is important that healthcare providers have a substantial knowledge of metabolic disorders for appropriate screening, diagnosis, and therapeutic options.[17] This can help prevent major complications associated with these conditions and thus call for training for healthcare providers to recognize warning signs of metabolic dysfunction as a measure to improve patient's outcome.[17] Lastly, lifestyle modifications should be encouraged as part of metabolic dysfunction management.[18] Creating awareness in the populace on the need for balanced diets and regular exercise can influence people's choices to their health benefits.[18] A culture of wellness, with emphasis on prevention through lifestyle changes, can reduce the ever-rising incidence of metabolic disorders.[18]

Metabolic dysfunction forms a significant area of research within the domains of clinical medicine and public health, given its impact on personal health outcomes and aggregate population-level economic costs.[19] To counter the rising incidence of metabolic disorder worldwide, educational and research efforts and healthcare methods will thus be crucial.[19] An expanded knowledge of metabolic functions and their impairments makes possible a range of more effective preventive measures and therapeutic treatments, likely to have greater positive impact on public health.

Types of metabolic dysfunction

Metabolic dysfunction encompasses a variety of disorders that disrupt normal metabolic processes in the body.[20] These dysfunctions can manifest in several forms, with metabolic syndrome and diabetes mellitus being two of the most prevalent and impactful conditions.[20] Additionally, other metabolic disorders such as Gaucher's disease and hemochromatosis further illustrate the complexity of metabolic dysfunction and its implications for health.[21,22]

Metabolic syndrome

Metabolic syndrome is cluster of interrelated risk factors those significantly increases likelihood of developing cardiovascular disease and type 2 diabetes.[23] in Fig. 1.



Fig. 1: Risk factors of metabolic syndrome.

1. **Insulin resistance:** When body become less responsive to insulin, making it difficult for glucose to enter cells.[24] Resulting, blood sugar levels rise, leading to higher insulin production by the pancreas.[23,24]
2. **Abdominal obesity:** Excess fat around waist.[25] It is typically measured by waist circumference, with thresholds set at over 35 inches for women and over 40 inches for men.[25,26]
3. **Dyslipidemia:** This refers to abnormal levels of lipids in the blood, specifically elevated triglycerides (150 mg/dL) and low levels of high-density lipoprotein (HDL) cholesterol (40 mg/dL for men and 50 mg/dL for women).[27,28]
4. **Hypertension:** This is another critical parameter, having systolic blood pressure of 130 mm Hg or diastolic pressure of 80 mm Hg.[29,30]

The presence of three or more of these components qualifies an individual for a diagnosis of metabolic syndrome.[26,30] Estimates suggest that up to one-third of adults in United States may be affected, due to obesity and sedentary lifestyles.[31]

Epidemiology and Risk factors of metabolic syndrome

Epidemiology of metabolic syndrome reveals significant variations across different populations and demographic groups. Key risk factors include:

1. **Obesity:** Excess body weight, particularly visceral fat accumulation, which is associated with metabolic syndrome development.[32]
2. **Physical inactivity:** Sedentary lifestyles contribute significantly to obesity and insulin resistance.[33]
3. **Family history:** A genetic predisposition to conditions like type 2 diabetes can increase an individual's risk for developing metabolic syndrome.[18]
4. **Dietary factors:** Saturated fats, sugars, and processed foods are implicated in development of metabolic syndrome.[34]
5. **Age and Ethnicity:** Risk for metabolic syndrome increases with age, and certain ethnic groups, such as Hispanic Americans, are at higher risk compared to others.[34]

Diabetes mellitus

Diabetes mellitus is form of metabolic dysfunction characterized by chronic hyperglycemia resulting from flaw in insulin secretion, insulin action.[35] There are two primary types: Type 1 diabetes and Type 2 diabetes, Given in Table 1.

Table 1: Distinguish Between Type 1 and Type 2 Diabetes.

Feature	Type 1 Diabetes	Type 2 Diabetes
Beginning	Childhood/adolescence	Typically, adulthood
Insulin Production	Little or none	Initially normal; may decrease over time
Treatment	Insulin therapy required	Lifestyle changes; may require medication/insulin
Body Weight	Often underweight	Often overweight or obese
Autoimmune Component	Yes	No

Insulin role in glucose metabolism

Insulin allows glucose to be absorbed into cells for energy.[36] In normal subjects, insulin is released by the pancreas when blood glucose levels are high following meals.[36]

- Glucose Influx: Insulin instructs muscle and fat cells to take up glucose from the blood.[37]
- Glycogen Synthesis: Insulin stimulates synthesis of excess glucose into glycogen in liver.[37]
- Inhibition of Gluconeogenesis: Insulin prevents the liver from producing glucose when the blood sugar levels are sufficient.[36]

In diabetes mellitus, especially Type 2 diabetes, this mechanism is impaired due to insulin resistance.[37] Cells fail to respond to the signals that insulin is sending, and hence hyperglycemia persists despite a rise in insulin production by the pancreas.[36,37] This can result in pancreatic beta-cell exhaustion and worsening of insulin output over time.

Other metabolic diseases

There are many other notable metabolic diseases besides metabolic syndrome and diabetes mellitus that significantly affect health:

1. Gaucher's disease

Gaucher's disease is a genetic condition due to the deficiency of the enzyme glucocerebrosidase that causes an accumulation of glucocerebroside within cells.[38] It is categorized into different types and thus appears differently depending on the type.[39] Given in Fig. 2.

Type 1 Gaucher's Disease: Most common; symptoms include anemia, fatigue, bone pain, and splenomegaly.[39,40]

Type 2 Gaucher's Disease: It is a severe neurological form that begins in infancy and progresses rapidly and often results in early death.[39,40]

Type 3 Gaucher's Disease: This is a chronic form with neurological symptoms but with slower progression than Type 2.[38,39]



Fig. 2: Normal cell Vs. Gaucher's Diseased cell.

Metabolic disturbance mainly relates to lipid metabolism due to enzyme deficiency, which causes various systemic complications.[39]

2. Hemochromatosis

Genetic disorder, where excessive iron absorption from food.[41] This disease leads to iron overload in liver, heart, and pancreas, among other organs. Its symptoms include:

- Fatigue
- Pain in the joints
- Abdominal pain
- Skin changes (Bronzing)

If left untreated, hemochromatosis may cause severe complications, including liver cirrhosis, diabetes ("bronze diabetes"), heart disease, and higher chances of liver cancer.[42]

Metabolic dysfunction includes a set of disorders that have serious consequences for health outcomes in an individual.[17] Lifestyle interventions, early diagnosis, and targeted treatments would be the need of the hour to handle these emerging diseases effectively.[1,7] With new findings in the field of research, there will be an increased demand for updating by health care professionals on novel findings of prevention techniques and therapies targeting metabolic improvement in all sections of society.[1,17,42]

Pathophysiology of metabolic dysfunction

Pathophysiology of metabolic dysfunction is complex, characterized by various interlinked mechanisms such as insulin resistance, chronic inflammation, oxidative stress, and role of adipose tissue as an endocrine organ.[43] Given in Fig. 3.



Fig. 3: Pathophysiology of metabolic dysfunction.

A. Insulin resistance

A hallmark of metabolic dysfunction, insulin resistance occurs due to a reduced response of cells of the body to insulin- it is a hormone that facilitates uptake and metabolism of glucose.[44] The mechanisms leading to the latter are multifactorial.[44]

The excess body fat, especially visceral fat, is significantly responsible for insulin resistance. Free fatty acids (FFAs) from adipose tissue interfere with insulin signaling pathways.[45] Increased FFAs inhibit glucose absorption in muscle cells also gluconeogenesis in the liver, thus worsening hyperglycemia.[45] Chronic low-grade inflammation is another important factor contributing to insulin resistance.[46] This inflammatory state can lead to further metabolic dysregulation.[46]

Oxidative Stress: Enhanced oxidative stress due to increased FFAs and inflammation damages cellular components, like insulin receptors.[47] ROS can activate stress-sensitive signaling pathways affecting insulin action, thereby promoting insulin resistance.[47]

B. Role of adipose tissue

It's an active endocrine organ maintaining metabolism.[48] It produces different hormones and cytokines, termed collectively as adipokines that have impacts on metabolism, inflammation, and insulin sensitivity.[49] Main adipokines are:

- Leptin: This hormone controls energy balance by suppressing appetite. In obesity, leptin levels are often high, but its activity is decreased because of leptin resistance.[50]
- Adiponectin: Unlike leptin, adiponectin increases the sensitivity of insulin and possesses anti-inflammatory properties.[51]
- Resistin: This adipokine is related with insulin resistance and inflammation. In obesity, high levels of resistin are responsible for impaired glucose metabolism.[52]

The balance of these hormones is essential to maintaining metabolic homeostasis.[52]

C. Chronic inflammation

Chronic inflammation is notification of metabolic dysfunction and plays important role in pathogenesis of obesity and type 2 diabetes.[53]

- Inflammatory cytokines: Excess adipose tissue releases inflammatory cytokines that impair the insulin signaling process. Thus, this creates a vicious cycle where inflammation leads to insulin resistance, which in turn increases the deposition of further fat.[54]
- Immune cell infiltration: The immune cells infiltrate into adipose tissue in obese, with macrophages being a part of this infiltration. The activated macrophages release extra pro-inflammatory cytokines that continue to perpetuate the inflammatory process.[55]
- Systemic effects: It is not only local tissue but also systemic effects in the organs like liver and skeletal muscle. For instance, elevated levels of TNF-α can cause hepatic insulin resistance and dyslipidemia.[56]

- Metabolic syndrome: Relation of obesity-induced inflammation and metabolic dysfunction leads to metabolic syndrome.[10,20]

D. Oxidative stress

When the body cannot detoxify or repair the harm brought on by an imbalance between the generation of reactive oxygen species and the body's capacity to detoxify these reactive intermediates, oxidative stress results.[57,58] In metabolic dysfunction, oxidative stress performs several critical roles:

- **Insulin resistance:** Elevated ROS levels can interfere with insulin signaling pathways by oxidizing key proteins in glucose uptake.[44] Oxidative modification reduces the effectiveness of insulin receptors on target tissues like muscle and liver cells.[44]
- **Lipid metabolism:** Free radicals attack lipids in cell membranes causing toxic byproducts that further increase inflammation and cellular dysfunction.[59]
- **Mitochondrial dysfunction:** Oxidative stress causes damage to mitochondrial DNA and proteins, impairs their function, reduces ATP production, and increases the generation of ROS feedback loop that worsens metabolic dysfunction.[60]
- **Cellular damage:** This leads to decreased insulin production with time, thereby compounding the issues related to glucose metabolism.[61]

Table 2: Mechanisms contributing to metabolic dysfunction.

Mechanism	Description	Implications
Insulin Resistance	Reduced cellular response to insulin due to excess FFAs and inflammatory cytokines	Leads to hyperglycemia; increases risk for type 2 diabetes
Role of Adipose Tissue	Adipose tissue secretes hormones (adipokines) affecting metabolism	Dysregulation contributes to systemic inflammation
Chronic Inflammation	Persistent low-grade inflammation from excess fat accumulation	Impairs insulin signaling; promotes metabolic syndrome
Oxidative Stress	Imbalance between ROS production and detoxification	Damages cellular structures; exacerbates metabolic dysfunction

These contribute together towards development of conditions like obesity and type 2 diabetes and enhance cardiovascular diseases through mechanisms like systemic inflammation and altered lipid metabolism.[28,59]

Risk factors for metabolic dysfunction

Metabolic dysfunction is caused by genetic predispositions, life-style choices, environmental influences.[62] Therefore, understanding these factors will help in developing appropriate prevention and treatment strategies.[62]

A. Genetic factors

Genetic factors are implicated in metabolic dysfunction. Hereditary factors may predispose people to different types of metabolic disorders, mainly through the inheritance of certain gene mutations or polymorphisms that impact metabolic pathways.[63]

a. Hereditary factors on metabolism

1. Polygenic nature of metabolic disorders: Most metabolic disorders are polygenic, which means they are caused by the additive effect of several genes.[64] For example, genetic factors responsible for 50% of cases of MetS.[65]
2. Specific genetic variants include: A number of genes have been shown to be related to metabolic dysfunction. Variants of the FTO gene predispose to obesity, mutations of the APOB, SLC2A2, and GCKR predispose lipid profiles.[66]
3. Hereditary metabolic disorders: These are disorders caused due to mutations in specific genes that lead to deficiencies in enzymes. Such disorders as phenylketonuria (PKU) and galactosemia clearly demonstrate how defects in a single gene can cause havoc in the normal metabolic processes, with devastating health effects if not properly managed4. Most of these disorders are autosomal recessive, which means that both parents must carry a defective gene for their child to be affected.[67]

Table 3: Common genetic factors associated with metabolic disorders.

Genetic factor	Associated condition	Description
FTO	Obesity	Variants increase susceptibility to weight gain
APOB	Dyslipidemia	Impacts lipid metabolism and cholesterol levels
SLC2A2	Hyperglycemia	Affects glucose transport in cells
GCKR	Insulin resistance	Influences glucose metabolism and insulin sensitivity
MTHFR	Homocystinuria	Impairs amino acid metabolism leading to cardiovascular risks

B. Lifestyle factors

Lifestyle factors greatly determine metabolic dysfunction risk. Lifestyle factors include diet and activity levels; hence lifestyle determines the state of an individual's metabolic system.[68]

C. Environmental factors

The risk for metabolic dysfunction is further shaped by environmental factors. Changes in urbanization, food availability, and lifestyles have all significantly contributed to the prevalence of these disorders.[68]

Clinical manifestations of metabolic dysfunction

Metabolic dysfunction is a broad term that encompasses several clinical manifestations that may affect the health of an individual.[69] The symptoms associated with metabolic disorders are very diverse and can be mild, which makes diagnosis sometimes delayed. Common symptoms include fatigue, weight changes, and other indicators that may suggest underlying metabolic issues.[70]

Metabolic Syndrome and Other diseases diagnostic features

A person is diagnosed with metabolic syndrome if they exhibit at least three of the five criteria listed below:

Table 4: Diagnostic criteria for metabolic syndrome.

Criteria	Measurement
Waist Circumference	>40 inches for men; >35 inches for women
Fasting Blood Triglycerides	≥150 mg/dL
HDL Cholesterol Levels	<40 mg/dL for men; <50 mg/dL for women
Blood Pressure	≥130/85 mmHg
Fasting Glucose Level	≥100 mg/dL

Diagnosis most often includes a combination of physical examinations and laboratory testing to measure these factors.[71]

Comorbidities

Metabolic disease is commonly complexed with several serious comorbidities that may further confuse an individual's health circumstances. Understanding these associations, therefore, is essential when developing management and prevention options.

1. Association with cardiovascular diseases

Patients with metabolic syndrome are far more likely to develop cardiovascular diseases (CVD).[72] Atherosclerosis, or the buildup of plaque in arterial walls that can cause heart attacks and strokes, is caused by the accumulation of risk factors such obesity, dyslipidemia (abnormal lipid levels), and hypertension.[72,73]

2. Non-Alcoholic Fatty Liver Disease (NAFLD)

An enormous buildup of liver fat, unrelated to alcohol, is the hallmark of this illness.[74] Insulin resistance and obesity are frequently linked to non-alcoholic steatohepatitis (NAFLD), which raises the risk of liver inflammation and, if ignored, can lead to cirrhosis or even liver cancer.[75]

3. Reproductive disorders

Metabolic dysfunction may also play a role in reproductive health.[76] Many women sufferings from PCOS have issues with their menstrual cycles, infertility, and signs of hyperandrogenism, and metabolic dysfunction only worsens such conditions.[77]

Pharmacological treatments

Pharmacological treatments are used when lifestyle measures alone cannot help manage metabolic dysfunction adequately.

1. Insulin Sensitizers: Metformin increases insulin response and lowers blood sugar levels in a patient.[78]
2. Statins: These lipid-lowering drugs reduce low-density lipoprotein (LDL) cholesterol levels, reducing risk of cardiovascular events in dyslipidemic patients.[79]
3. Antihypertensives: Drugs like ACE inhibitors are utilized to treat high blood pressure condition.[80]
4. GLP-1 Receptor Agonists: These drugs do not only help in regulating blood glucose but also improve weight loss due to delayed gastric emptying.[80]

Table 5: Current treatments for metabolic dysfunction.

Drug Name	Dose	Application	Novel Drug Delivery Systems
Metformin	500 mg to 2000 mg/day	First-line drug in type 2 diabetes and insulin resistance.	Extended-release formulations for improved adherence.
Atorvastatin	10 mg to 80 mg/day	Used to lower LDL cholesterol and reduce cardiovascular risk.	Lipid-based nanoparticles for targeted delivery.
Ezetimibe	10 mg/day	Reduces cholesterol absorption in the intestines.	Micelle formulations for enhanced bioavailability.
Lisinopril	10 mg to 40 mg/day	Antihypertensive agent used to manage high blood	Transdermal patches for sustained release.

		pressure.	
Pioglitazone	15 mg to 45 mg/day	Insulin sensitizer used in type 2 diabetes management.	Controlled-release tablets for consistent dosing.
Sitagliptin	100 mg/day	Inhibitor of DPP-4 that lowers glucagon levels and boosts insulin secretion.	Oral disintegrating tablets for faster absorption.
GLP-1 Agonists (e.g., Liraglutide)	0.6 mg to 1.8 mg/day (subcutaneous)	Increases insulin secretion and promotes weight loss.	Pen injectors with prefilled doses for ease of use.
Farnesoid X Receptor (Obeticholic Acid)	10 mg to 25 mg/day	Investigational drugs targeting NAFLD and metabolic syndrome components.	Sustained-release formulations under development.
Omega-3 Fatty Acids (EPA/DHA)	1 g - 4 g/day	Used to lower triglycerides and improve lipid profiles.	Emulsified formulations for improved absorption.
Probiotics	Varies by strain	May improve gut health and influence metabolic parameters.	Encapsulated delivery systems for targeted gut release.

Future perspectives

With metabolic dysfunction rates soaring worldwide, the need for new research and public health strategies is becoming a pressing matter to be dealt with. The following are future research directions that should be considered. First, genetic factors that lead to metabolic dysfunction must be understood so that treatments may be designed accordingly. Targeted interventions might be developed for specific genes that increase the risk for conditions such as insulin resistance and obesity. Moreover, there is growing interest in identifying new therapeutic targets that can simultaneously target multiple aspects of metabolic dysfunction. Exploring pathways that relate to inflammation and gut health may lead to medicines that treat several components of metabolic syndrome at once. For example, epigenetic studies on how the environment determines gene expression could lead to preventive approaches specific to a particular individual.

Advanced imaging techniques may open our eyes to understanding metabolism better, as changes in fat distribution and organ functions are now visible in real time. Techniques like MRI and PET scans provide further insights into how such a condition develops and progresses in a patient. It has also become important to provide patient-centric care with variations in genetics and lifestyle across different patients. Proper prevention and management strategies should also be in place on the public health front, this time at the community level. Education programs on issues related to metabolic dysfunction and risk factors should also reach the community level. Promoting physical activity through organized walking groups, fitness classes, and recreational sports leagues can combat sedentary lifestyles.

CONCLUSION

Metabolic dysfunction thus presents an important and increasingly difficult public health challenge characterized by an extremely wide variety of disorders affecting normal metabolic processes. Pathologies of metabolic dysfunction feature many serious health changes like insulin resistance, chronic inflammation, oxidative stress, and others. It is managed best by the most multilateral approach of treatment-its preventive public health and combined use of lifestyle modifications with drug interventions. Educational efforts on healthy diets and regular physical activity should be implemented to empower people in making informed choices that promote metabolic health. Further research into genetic predispositions and potential therapeutic targets is also important for developing more effective treatments. The number of cases of metabolic disorders continues to grow worldwide; hence, providers in health care require some up-to-date information to ensure that their patients remain in good metabolic health pathways. It will enhance systems supporting these practices by reducing the number of those diseases within that community with the strengthening of relationships among professionals in service, researchers, and other populations within that community.

REFERENCES

1. Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, et al. The Metabolic Syndrome. Endocr Rev [Internet], 2008, 1 [2024, 28]; 29(7): 777–822. Available from: https://doi.org/10.1210/er.2008-0024
2. Aron-Wisnewsky J, Warmbrunn MV, Nieuwdorp M, Clément K. Metabolism and Metabolic Disorders and the Microbiome: The Intestinal Microbiota Associated With Obesity, Lipid Metabolism, and Metabolic Health—Pathophysiology and Therapeutic Strategies. Gastroenterology [Internet], 2021, 1 [2024, 28]; 160(2): 573–99. Available from: https://www.sciencedirect.com/science/article/pii/S0016508520355050

3. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. The Lancet [Internet], 2005, 16 [2024, 28]; 365(9468): 1415–28. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)66378-7/abstract
4. Demidova IY, Ю ДИ, Boeva VV, В БВ. Screening, diagnosis and treatment of early carbohydrate metabolism disorders. Pharmateca [Internet], 2024, 23 [2024, 28]; 31(2): 85–91. Available from: https://doi.org/10.18565/pharmateca.2024.2.84-91
5. Fahed G, Aoun L, Bou Zerdan M, Allam S, Bou Zerdan M, Bouferraa Y, et al. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Int J Mol Sci [Internet], 2022 [2024, 28]; 23(2): 786. Available from: https://www.mdpi.com/1422-0067/23/2/786
6. Ferreira CR, Rahman S, Keller M, Zschocke J, Group IA. An international classification of inherited metabolic disorders (ICIMD). J Inherit Metab Dis [Internet], 2021 [2024, 28]; 44(1): 164–77. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/jimd.12348
7. Han TS, Lean MEJ. Metabolic syndrome. Medicine (Baltimore) [Internet], 2015, 1 [2024, 28]; 43(2): 80–7. Available from: https://www.sciencedirect.com/science/article/pii/S1357303914003302
8. Karra P, Winn M, Pauleck S, Bulsiewicz-Jacobsen A, Peterson L, Coletta A, et al. Metabolic dysfunction and obesity-related cancer: Beyond obesity and metabolic syndrome. Obesity [Internet], 2022 [2024, 28]; 30(7): 1323–34. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/oby.23444
9. Lemmer IL, Willemsen N, Hilal N, Bartelt A. A guide to understanding endoplasmic reticulum stress in metabolic disorders. Mol Metab [Internet], 2021, 1 [28]; 47: 101169. Available from: https://www.sciencedirect.com/science/article/pii/S2212877821000090
10. Samson SL, Garber AJ. Metabolic Syndrome. Endocrinol Metab Clin [Internet], 2014, 1 [2024, 28]; 43(1): 1–23. Available from: https://www.endo.theclinics.com/article/S0889-8529(13)00108-4/abstract
11. Slee AD. Exploring metabolic dysfunction in chronic kidney disease. Nutr Metab [Internet], 2012, 26 [2024, 28]; 9(1): 36. Available from: https://doi.org/10.1186/1743-7075-9-36
12. Tilg H, Kaser A. Gut microbiome, obesity, and metabolic dysfunction. J Clin Invest [Internet], 2011, 1 [2024, 28]; 121(6): 2126–32. Available from: https://www.jci.org/articles/view/58109

13. Bick SL, Nathan A, Park H, Green RC, Wojcik MH, Gold NB. Estimating the sensitivity of genomic newborn screening for treatable inherited metabolic disorders. Genet Med [Internet], 2025, 1 [2024, 28]; 27(1): 101284. Available from: https://www.sciencedirect.com/science/article/pii/S1098360024002181
14. Taube A, Schlich R, Sell H, Eckardt K, Eckel J. Inflammation and metabolic dysfunction: links to cardiovascular diseases. Am J Physiol-Heart Circ Physiol [Internet], 2012 [2024, 28]; 302(11): H2148–65. Available from: https://journals.physiology.org/doi/full/10.1152/ajpheart.00907.2011
15. Tucker P, Marquié JC, Folkard S, Ansiau D, Esquirol Y. Shiftwork and Metabolic Dysfunction. Chronobiol Int [Internet], 2012, 1 [2024, 28]; 29(5): 549–55. Available from: https://doi.org/10.3109/07420528.2012.675259
16. Zorena K, Jachimowicz-Duda O, Ślęzak D, Robakowska M, Mrugacz M. Adipokines and Obesity. Potential Link to Metabolic Disorders and Chronic Complications. Int J Mol Sci [Internet], 2020 [2024, 28]; 21(10): 3570. Available from: https://www.mdpi.com/1422-0067/21/10/3570
17. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and Management of the Metabolic Syndrome. Circulation [Internet], 2005; 25 [2024, 28]; 112(17): 2735–52. Available from: https://www.ahajournals.org/doi/10.1161/circulationaha.105.169404
18. Grave RD, Calugi S, Centis E, Marzocchi R, Ghoch ME, Marchesini G. Lifestyle modification in the management of the metabolic syndrome: achievements and challenges. Diabetes Metab Syndr Obes Targets Ther [Internet], 2010, 2 [2024, 28]; 3: 373–85. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047997/
19. Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol [Internet], 2020, 1 [2024, 28]; 73(1): 202–9. Available from: https://www.journal-of-hepatology.eu/article/S0168-8278%2820%2930201-4/fulltext
20. Swarup S, Ahmed I, Grigorova Y, Zeltser R. Metabolic Syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2024 [2024, 28]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK459248/
21. Hertz E, Chen Y, Sidransky E. Gaucher disease provides a unique window into Parkinson disease pathogenesis. Nat Rev Neurol [Internet], 2024 [2024, 28]; 20(9): 526–40. Available from: https://www.nature.com/articles/s41582-024-00999-z

22. Olynyk JK, Ramm GA. Hemochromatosis. N Engl J Med [Internet], 2022, 7 [2024, 28]; 387(23): 2159–70. Available from: https://www.nejm.org/doi/full/10.1056/NEJMra2119758
23. O'Neill BJ. Effect of low-carbohydrate diets on cardiometabolic risk, insulin resistance, and metabolic syndrome. Curr Opin Endocrinol Diabetes Obes [Internet], 2020 [2024; 28]; 27(5): 301. Available from: https://journals.lww.com/co-endocrinology/abstract/2020/10000/effect_of_low_carbohydrate_diets_on.9.aspx
24. Zhao J, Duan L, Li J, Yao C, Wang G, Mi J, et al. New insights into the interplay between autophagy, gut microbiota and insulin resistance in metabolic syndrome. Biomed Pharmacother [Internet], 2024, 1 [2024, 28]; 176: 116807. Available from: https://www.sciencedirect.com/science/article/pii/S0753332224006917
25. AHMADI N, SADR SM, MOHAMMADI MR, MIRZAEI M, MEHRPARVAR AH, YASSINI ARDEKANI SM, et al. Prevalence of Abdominal Obesity and Metabolic Syndrome in Children and Adolescents: A Community Based Cross-Sectional Study. Iran J Public Health [Internet], 2020 [2024, 28]; 49(2): 360–8. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231702/
26. Jayawardena R, Sooriyaarachchi P, Misra A. Abdominal obesity and metabolic syndrome in South Asians: prevention and management. Expert Rev Endocrinol Metab [Internet], 2021, 2 [2024, 28]; 16(6): 339–49. Available from: https://doi.org/10.1080/17446651.2021.1982381
27. Makhoul E, Aklinski JL, Miller J, Leonard C, Backer S, Kahar P, et al. A Review of COVID-19 in Relation to Metabolic Syndrome: Obesity, Hypertension, Diabetes, and Dyslipidemia. Cureus [Internet]. [2024, 28]; 14(7): e27438. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420458/
28. Ishrat S, Hussain M. Prevalence of Insulin Resistance, Dyslipidemia and Metabolic Syndrome in Infertile Women with Polycystic Ovary Syndrome. J Bangladesh Coll Physicians Surg [Internet], 2021, 30 [2024, 28]; 39(4): 225–32. Available from: https://banglajol.info/index.php/JBCPS/article/view/55943
29. Litwin M, Kułaga Z. Obesity, metabolic syndrome, and primary hypertension. Pediatr Nephrol [Internet], 2021, 1 [2024, 28]; 36(4): 825–37. Available from: https://doi.org/10.1007/s00467-020-04579-3
30. Katsimardou A, Imprialos K, Stavropoulos K, Sachinidis A, Doumas M, Athyros V. Hypertension in Metabolic Syndrome: Novel Insights. Curr Hypertens Rev, 2020; 1, 16(1): 12–8.

31. Chen R, Safiri S, Behzadifar M, Kong JD, Zguira MS, Bragazzi NL, et al. Health Effects of Metabolic Risks in the United States From 1990 to 2019. Front Public Health [Internet], 2022, 31 [2024, 28]; 10: 751126. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841675/
32. Engin A. The Definition and Prevalence of Obesity and Metabolic Syndrome: Correlative Clinical Evaluation Based on Phenotypes. In: ENGIN AB, ENGIN A, editors. Obesity and Lipotoxicity [Internet]. Cham: Springer International Publishing, 2024; [202, 28]: 1–25. Available from: https://doi.org/10.1007/978-3-031-63657-8_1
33. Kallio P, Pahkala K, Heinonen OJ, Tammelin TH, Pälve K, Hirvensalo M, et al. Physical inactivity from youth to adulthood and adult cardiometabolic risk profile. Prev Med [Internet], 2021, 1 [2024, 28]; 145: 106433. Available from: https://www.sciencedirect.com/science/article/pii/S0091743521000177
34. Castro-Barquero S, Ruiz-León AM, Sierra-Pérez M, Estruch R, Casas R. Dietary Strategies for Metabolic Syndrome: A Comprehensive Review. Nutrients [Internet], 2020; [2024, 28]; 12(10): 2983. Available from: https://www.mdpi.com/2072-6643/12/10/2983
35. Dilworth L, Facey A, Omoruyi F. Diabetes Mellitus and Its Metabolic Complications: The Role of Adipose Tissues. Int J Mol Sci [Internet], 2021 [2024, 28]; 22(14): 7644. Available from: https://www.mdpi.com/1422-0067/22/14/7644
36. Rahman MS, Hossain KS, Das S, Kundu S, Adegoke EO, Rahman MA, et al. Role of Insulin in Health and Disease: An Update. Int J Mol Sci [Internet], 2021 [2024; 28]; 22(12): 6403. Available from: https://www.mdpi.com/1422-0067/22/12/6403
37. Norton L, Shannon C, Gastaldelli A, DeFronzo RA. Insulin: The master regulator of glucose metabolism. Metabolism [Internet], 2022, 1 [2024, 28]; 129: 155142. Available from: https://www.sciencedirect.com/science/article/pii/S0026049522000208
38. Kartha RV, Terluk MR, Brown R, Travis A, Mishra UR, Rudser K, et al. Patients with Gaucher disease display systemic oxidative stress dependent on therapy status. Mol Genet Metab Rep [Internet], 2020, 1 [2024, 28]; 25: 100667. Available from: https://www.sciencedirect.com/science/article/pii/S2214426920301130
39. Reyhani-Ardabili M, Fathi M, Ghafouri-Fard S. Application of CRISPR/Cas9 technology in the modeling of Gaucher disorder. Biochem Biophys Rep [Internet], 2024, 1 [2024, 28]; 40: 101872. Available from: https://www.sciencedirect.com/science/article/pii/S240558082400236X
40. Rodrigues KF, Yong WTL, Bhuiyan MSA, Siddiquee S, Shah MD, Venmathi Maran BA. Current Understanding on the Genetic Basis of Key Metabolic Disorders: A Review.

Biology [Internet], 2022 [2024, 28]; 11(9): 1308. Available from: https://www.mdpi.com/2079-7737/11/9/1308

41. Barbalho SM, Laurindo LF, Tofano RJ, Flato UAP, Mendes CG, de Alvares Goulart R, et al. Dysmetabolic Iron Overload Syndrome: Going beyond the Traditional Risk Factors Associated with Metabolic Syndrome. Endocrines [Internet], 2023 [2024, 28]; 4(1): 18–37. Available from: https://www.mdpi.com/2673-396X/4/1/2
42. Barton JC, Acton RT. Diabetes in HFE Hemochromatosis. J Diabetes Res [Internet], 2017 [2024, 28]; 2017(1): 9826930. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1155/2017/9826930
43. Cavalera M, Wang J, Frangogiannis NG. Obesity, metabolic dysfunction, and cardiac fibrosis: pathophysiological pathways, molecular mechanisms, and therapeutic opportunities. Transl Res [Internet], 2014, 1 [2024, 28]; 164(4): 323–35. Available from: https://www.sciencedirect.com/science/article/pii/S1931524414001649
44. Mikhail N. The metabolic syndrome: Insulin resistance. Curr Hypertens Rep [Internet], 2009, 1 [2024, 28]; 11(2): 156–8. Available from: https://doi.org/10.1007/s11906-009-0027-4
45. Hsueh WA, Quiñones MJ. Role of endothelial dysfunction in insulin resistance. Am J Cardiol [Internet], 2003; 18 [2024, 28]; 92(4, 1): 10–7. Available from: https://www.sciencedirect.com/science/article/pii/S0002914903006118
46. McCracken E, Monaghan M, Sreenivasan S. Pathophysiology of the metabolic syndrome. Clin Dermatol [Internet], 2018, 1 [2024, 28]; 36(1): 14–20. Available from: https://www.sciencedirect.com/science/article/pii/S0738081X1730158X
47. Mahjoub S, Masrour-Roudsari J. Role of oxidative stress in pathogenesis of metabolic syndrome. Casp J Intern Med [Internet], 2012 [2024, 28]; 3(1): 386–96. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4600138/
48. Laclaustra M, Corella D, Ordovas JM. Metabolic syndrome pathophysiology: The role of adipose tissue. Nutr Metab Cardiovasc Dis [Internet], 2007; 1 [2024, 28], 17(2): 125–39. Available from: https://www.sciencedirect.com/science/article/pii/S0939475306002316
49. Richard AJ, White U, Elks CM, Stephens JM. Adipose Tissue: Physiology to Metabolic Dysfunction. In: Endotext [Internet] [Internet]. MDText.com, Inc, 2020 [2024, 28]. Available from: https://www.ncbi.nlm.nih.gov/sites/books/NBK555602/
50. Obradovic M, Sudar-Milovanovic E, Soskic S, Essack M, Arya S, Stewart AJ, et al. Leptin and Obesity: Role and Clinical Implication. Front Endocrinol [Internet], 2021; 18 [2024; 28]; 12. Available from:

https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2021.585887/full

51. Zhao S, Kusminski CM, Scherer PE. Adiponectin, Leptin and Cardiovascular Disorders. Circ Res [Internet], 2021, 8 [2024, 28], 128(1): 136–49. Available from: https://www.ahajournals.org/doi/full/10.1161/CIRCRESAHA.120.314458
52. Tripathi D, Kant S, Pandey S, Ehtesham NZ. Resistin in metabolism, inflammation, and disease. FEBS J [Internet], 2020 [2024, 28]; 287(15): 3141–9. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/febs.15322
53. Dabravolski SA, Nikiforov NG, Eid AH, Nedosugova LV, Starodubova AV, Popkova TV, et al. Mitochondrial Dysfunction and Chronic Inflammation in Polycystic Ovary Syndrome. Int J Mol Sci [Internet], 2021 [2024, 28]; 22(8): 3923. Available from: https://www.mdpi.com/1422-0067/22/8/3923
54. Varra FN, Varras M, Varra VK, Theodosis-Nobelos P. Molecular and pathophysiological relationship between obesity and chronic inflammation in the manifestation of metabolic dysfunctions and their inflammation‑mediating treatment options (Review). Mol Med Rep [Internet], 2024, 1 [2024, 28]; 29(6): 1–27. Available from: https://www.spandidos-publications.com/10.3892/mmr.2024.13219
55. Zhou Y, Shi W, Zhao D, Xiao S, Wang K, Wang J. Identification of Immune-Associated Genes in Diagnosing Aortic Valve Calcification With Metabolic Syndrome by Integrated Bioinformatics Analysis and Machine Learning. Front Immunol [Internet], 2022, 4 [2024, 28]; 13. Available from: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.937886/full
56. Moon S, Kang J, Kim SH, Chung HS, Kim YJ, Yu JM, et al. Beneficial Effects of Time-Restricted Eating on Metabolic Diseases: A Systemic Review and Meta-Analysis. Nutrients [Internet], 2020 [2024, 28]; 12(5): 1267. Available from: https://www.mdpi.com/2072-6643/12/5/1267
57. Masenga SK, Kabwe LS, Chakulya M, Kirabo A. Mechanisms of Oxidative Stress in Metabolic Syndrome. Int J Mol Sci [Internet], 2023 [2024; 28]; 24(9): 7898. Available from: https://www.mdpi.com/1422-0067/24/9/7898
58. Gensluckner S, Wernly B, Datz C, Aigner E. Iron, Oxidative Stress, and Metabolic Dysfunction—Associated Steatotic Liver Disease. Antioxidants [Internet], 2024 [2024; 28], 13(2): 208. Available from: https://www.mdpi.com/2076-3921/13/2/208

59. Natesan V, Kim SJ. Lipid Metabolism, Disorders and Therapeutic Drugs – Review. Biomol Ther [Internet], 2021; 1 [2024, 28]; 29(6): 596–604. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8551734/
60. Prasun P. Mitochondrial dysfunction in metabolic syndrome. Biochim Biophys Acta BBA - Mol Basis Dis [Internet], 2020, 1 [2024, 28]; 1866(10): 165838. Available from: https://www.sciencedirect.com/science/article/pii/S092544392030185X
61. Amorim JA, Coppotelli G, Rolo AP, Palmeira CM, Ross JM, Sinclair DA. Mitochondrial and metabolic dysfunction in ageing and age-related diseases. Nat Rev Endocrinol [Internet], 2022 [2024, 28]; 18(4): 243–58. Available from: https://www.nature.com/articles/s41574-021-00626-7
62. Lekakis V, Papatheodoridis GV. Natural history of metabolic dysfunction-associated steatotic liver disease. Eur J Intern Med [Internet], 2024, 1 [2024, 28]; 122: 3–10. Available from: https://www.sciencedirect.com/science/article/pii/S0953620523003977
63. Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease - ScienceDirect [Internet]. [2024, 28]. Available from: https://www.sciencedirect.com/science/article/pii/S0168827821021504
64. Wallis N, Raffan E. The Genetic Basis of Obesity and Related Metabolic Diseases in Humans and Companion Animals. Genes [Internet], 2020 [2024, 28]; 11(11): 1378. Available from: https://www.mdpi.com/2073-4425/11/11/1378
65. Lee S, Kim SA, Hong J, Kim Y, Hong G, Baik S, et al. Identification of genetic variants related to metabolic syndrome by next-generation sequencing. Diabetol Metab Syndr [Internet], 2022, 23 [2024, 28], 14: 119. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396768/
66. Barroso I, McCarthy MI. The genetic basis of metabolic disease. Cell [Internet], 2019; 21 [2024, 28], 177(1): 146. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC6432945/
67. Rajkumar V, Dumpa V. Lysosomal Storage Disease. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2024 [2024, 28]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK563270/
68. Deng Y, Yang Q, Hao C, Wang HH, Ma T, Chen X, et al. Combined lifestyle factors and metabolic syndrome risk: a systematic review and meta-analysis. Int J Obes [Internet], 2024, 8 [2024, 28]; 1–11. Available from: https://www.nature.com/articles/s41366-024-01671-8

69. Merritt JL, MacLeod E, Jurecka A, Hainline B. Clinical manifestations and management of fatty acid oxidation disorders. Rev Endocr Metab Disord [Internet], 2020, 1 [2024, 28]; 21(4): 479–93. Available from: https://doi.org/10.1007/s11154-020-09568-3
70. Chang C, Greenspan A, Gershwin ME. The pathogenesis, diagnosis and clinical manifestations of steroid-induced osteonecrosis. J Autoimmun [Internet], 2020, 1 [2024, 28]; 110: 102460. Available from: https://www.sciencedirect.com/science/article/pii/S0896841120300767
71. Lemieux I, Després JP. Metabolic Syndrome: Past, Present and Future. Nutrients [Internet], 2020[2024, 28]; 12(11): 3501. Available from: https://www.mdpi.com/2072-6643/12/11/3501
72. Lee H, Lee Y ho, Kim SU, Kim HC. Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study. Clin Gastroenterol Hepatol [Internet], 2021, 1 [2024, 28]; 19(10): 2138-2147.e10. Available from: https://www.sciencedirect.com/science/article/pii/S1542356520317171
73. Silveira Rossi JL, Barbalho SM, Reverete de Araujo R, Bechara MD, Sloan KP, Sloan LA. Metabolic syndrome and cardiovascular diseases: Going beyond traditional risk factors. Diabetes Metab Res Rev [Internet], 2022 [2024, 28]; 38(3): e3502. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/dmrr.3502
74. Tang A, Ng CH, Phang PH, Chan KE, Chin YH, Fu CE, et al. Comparative Burden of Metabolic Dysfunction in Lean NAFLD vs Non-lean NAFLD - A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol [Internet], 2023, 1 [2024, 28]; 21(7): 1750-1760.e12. Available from: https://www.sciencedirect.com/science/article/pii/S1542356522006693
75. Kim D, Konyn P, Sandhu KK, Dennis BB, Cheung AC, Ahmed A. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J Hepatol [Internet], 2021, 1 [2024, 28]; 75(6): 1284–91. Available from: https://www.sciencedirect.com/science/article/pii/S0168827821019644
76. Thong EP, Codner E, Laven JSE, Teede H. Diabetes: a metabolic and reproductive disorder in women. Lancet Diabetes Endocrinol [Internet], 2020, 1 [2024, 28]; 8(2): 134–49. Available from: https://www.thelancet.com/journals/landia/article/PIIS2213-8587(19)30345-6/abstract
77. Choudhury AA, Devi Rajeswari V. Gestational diabetes mellitus - A metabolic and reproductive disorder. Biomed Pharmacother [Internet], 2021; 1 [2024, 28]; 143: 112183. Available from: https://www.sciencedirect.com/science/article/pii/S0753332221009677

78. Mastrototaro L, Roden M. Insulin resistance and insulin sensitizing agents. Metabolism [Internet], 2021, 1 [2024; 28]; 125: 154892. Available from: https://www.sciencedirect.com/science/article/pii/S002604952100192X
79. Mellemkjær A, Kjær MB, Haldrup D, Grønbæk H, Thomsen KL. Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease. Eur J Intern Med [Internet], 2024, 1 [2024, 28]; 122: 28–34. Available from: https://www.sciencedirect.com/science/article/pii/S0953620523004090
80. Maciorowska M, Krzesiński P, Wierzbowski R, Gielerak G. Heart Rate Variability in Patients with Hypertension: the Effect of Metabolic Syndrome and Antihypertensive Treatment. Cardiovasc Ther [Internet], 2020 [2024, 28]; 2020(1): 8563135. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1155/2020/856313